Loading the security overview…
Where the tokens are
Trade IBRXStandardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.24M | $44.21M | $38.29M | $32.06M | $26.43M | $16.52M | $7.55M | $6.11M |
| Cost of revenue | $298.00K | $238.00K | $382.00K | $177.00K | $136.00K | $58.00K | $0 | $0 |
| Gross profit | $50.94M | $43.97M | $37.90M | $31.88M | $26.29M | $16.46M | $7.55M | $6.11M |
| Gross margin | 99.4% | 99.5% | 99.0% | 99.4% | 99.5% | 99.6% | 100.0% | 100.0% |
| Research and development | $60.82M | $67.99M | $63.86M | $51.23M | $55.24M | $48.23M | $35.22M | $50.44M |
| Selling, general and administrative | $51.82M | $45.77M | $38.73M | $36.28M | $42.34M | $32.65M | $41.73M | $35.92M |
| Operating expenses | $112.64M | $113.76M | $102.59M | $87.51M | $97.57M | $80.89M | $76.95M | $86.36M |
| Operating income | −$61.70M | −$69.79M | −$64.68M | −$55.63M | −$71.29M | −$64.43M | −$69.40M | −$80.25M |
| Operating margin | -120.4% | -157.9% | -169.0% | -173.5% | -269.8% | -390.1% | -919.0% | -1314.3% |
| EBITDA | −$57.29M | −$65.41M | −$60.82M | −$51.68M | −$67.41M | −$60.60M | −$65.26M | −$75.80M |
| Interest income | $0 | $0 | $2.30M | $2.07M | $0 | $0 | $1.19M | $1.80M |
| Interest expense | −$31.24M | −$28.46M | −$27.19M | −$27.58M | −$28.88M | −$28.87M | −$37.57M | −$40.25M |
| Income before taxes | −$230.39M | −$632.79M | −$62.09M | −$67.31M | −$92.31M | −$129.90M | −$59.18M | −$85.75M |
| Income taxes | $0 | $9.00K | −$135.00K | −$35.00K | $269.00K | −$234.00K | $0 | — |
| Net income | −$230.39M | −$632.80M | −$61.96M | −$67.27M | −$92.57M | −$129.67M | −$59.18M | −$85.75M |
| Net margin | -449.6% | -1431.5% | -161.8% | -209.8% | -350.3% | -785.0% | -783.6% | -1404.4% |
| EPS, basic | −$0.22 | −$0.62 | −$0.06 | −$0.07 | −$0.10 | −$0.15 | −$0.08 | −$0.12 |
| EPS, diluted | −$0.22 | −$0.62 | −$0.06 | −$0.07 | −$0.10 | −$0.15 | −$0.08 | −$0.14 |
| Diluted shares | 1.05B | 1.03B | 991.47M | 946.60M | 888.22M | 853.16M | 744.04M | 697.96M |
Figures describe ImmunityBio, shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.